Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Niedzwieski, D.; Knox, J. J.; Kaubisch, A.; Posey, J.; Tan, B. R.; Kavan, P.; Goel, R.; Murray, J. J.; Bekaii-Saab, T. S.; Tam, V. C.; Rajdev, L.; Kelley, R. K.; Siegel, A.; Balletti, J.; Harding, J. J.; Schwartz, L. H.; Goldberg, R. M.; Bertagnolli, M. M.; Venook, A. P. |
| Abstract Title: | Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance) |
| Meeting Title: | 2016 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2016 21-23 Jan |
| Meeting Location: | San Franciscon, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-02-01 |
| Language: | English |
| ACCESSION: | WOS:000378109600186 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2016.34.4_suppl.192 |
| Notes: | Meeting Abstract: 192 -- Gastrointestinal Cancers Symposium -- JAN 21-23, 2016 -- San Francisco, CA -- S -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work